ImmunoGen (NASDAQ:IMGN) Earns Neutral Rating from Piper Sandler
Piper Sandler reiterated their neutral rating on shares of ImmunoGen (NASDAQ:IMGN – Free Report) in a report issued on Monday morning, Benzinga reports. They currently have a $31.00 price objective on the biotechnology company’s stock, up from their previous price objective of $24.00. IMGN has been the topic of a number of other research reports. […]
More Stories
California Delays Revoking 17,000 CDLs Until March After Immigrants Sue
By Jill McLaughlin California announced on Dec. 30 it would delay revoking 17,000 commercial driver’s licenses (CDLs) until March after...
In Texas, a 400-Acre Muslim Development Sparks Controversy
By Darlene McCormick Sanchez JOSEPHINE, Texas—This rural town with farmland stretching to the horizon might as well be a million...
UN to Cut 2,900 Jobs, $570 Million in Budget Following US Scrutiny: Ambassador Bartos
By Naveen Athrappully The United Nations has adopted a “leaner, better prioritized” regular budget for 2026 that saves $570 million...
SNAP Bans on Soda, Candy in 5 States to Begin on Jan. 1
By Kimberly Hatek Residents in five states receiving federal food assistance will face new restrictions on their benefits when it...
Trump Issues First Vetoes of Second Presidential Term
By Joseph Lord President Donald Trump has issued the first presidential vetoes of his second term in office, overriding two...
Disney to Pay $10 Million to Resolve Children’s Privacy Claims
By Bill Pan Disney will pay $10 million to settle allegations that it violated a federal children’s privacy law through...